The U.S. Supreme Court declined to hear multiple challenges to the Inflation Reduction Act’s (IRA) Medicare prescription drug price negotiation program, including cases brought by major biopharma companies. The justices’ refusal to take up the petitions effectively ends the current legal attempt to overturn the negotiation framework. The denied petitions included suits involving AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk, following earlier losses in lower courts. AstraZeneca’s petition mirrored arguments that the process deprived it of rights tied to patent-backed pricing and market alternatives, while plaintiffs contended the “negotiation” structure was not genuine. For the industry, the decision confirms the negotiation mechanism remains in force, reinforcing planning assumptions for Medicare pricing impacts across affected product portfolios.